Discovery of cathepsin S inhibitor LY3000328 for the treatment of abdominal aortic aneurysm

ACS Medicinal Chemistry Letters

Volumn 5, Issue 10, 2014, Pages 1138-1142

  Jadhav, Prabhakar K ^a   Schiffler, Matthew A ^a   Gavardinas, Kostas ^a   Kim, Euibong J ^a   Matthews, Donald P ^a   Staszak, Michael A ^a   Coffey, D Scott ^a   Shaw, Bruce W ^a   Cassidy, Kenneth C ^a   Brier, Richard A ^a   Zhang, Yuke ^a   Christie, Robert M ^a   Matter, William F ^a   Qing, Keyun ^a   Durbin, Jim D ^a   Wang, Yong ^a   Deng, Gary G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

abdominal aortic aneurysm; Cathepsin; development candidate; noncovalent

Indexed keywords

CATHEPSIN S INHIBITOR; LY 3000328; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BINDING; DRUG DISPOSITION; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROCESS OPTIMIZATION;

EID: 84907942042     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500283g     Document Type: Article

References (24)

1. Wilmink, T. B.; Quick, C. R.; Hubbard, C. S.; Day, N. E. The influence of screening on the incidence of ruptured abdominal aortic aneurysms J. Vasc. Surg. 1999, 30, 203-208
2. Lederle, F. A.; Johnson, G. R.; Wilson, S. E.; Chute, E. P.; Hye, R. J.; Makaroun, M. S.; Barone, G. W.; Bandyk, D.; Moneta, G. L.; Makhoul, R. G. Aneurysm detection and management veterans affairs cooperative study investigators. The aneurysm detection and management study screening program: validation cohort and final results Arch. Int. Med. 2000, 160, 1425-1430
3. Ashton, H. A.; Buxton, M. J.; Day, N. E.; Kim, L. G.; Marteau, T. M.; Scott, R. A.; Thompson, S. G.; Walker, N. M. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial Lancet 2002, 360, 1531-1539
4. Lawrence-Brown, M. M.; Norman, P. E.; Jamrozik, K.; Semmens, J. B.; Donnelly, N. J.; Spencer, C.; Tuohy, R. Initial results of ultrasound screening for aneurysm of the abdominal aorta in Western Australia: relevance for endoluminal treatment of aneurysm disease Cardiovasc. Surg. 2001, 9, 234-240
5. Wilmink, A. B.; Quick, C. R. Epidemiology and potential for prevention of abdominal aortic aneurysm Br. J. Surg. 1998, 85, 155-162
6. Lindholt, J. S.; Juul, S.; Fasting, H.; Henneberg, E. W. Hospital costs and benefits of screening for abdominal aortic aneurysms: results from a randomised population screening trial Eur. J. Vasc. Endovasc. Surg. 2002, 23, 55-60
7. Kent, K. C.; Zwolak, R. M.; Jaff, M. R.; Hollenbeck, S. T.; Thompson, R. W.; Schermerhorn, M. L.; Sicard, G. A.; Riles, T. S.; Cronenwett, J. L. Screening for abdominal aortic aneurysm: a consensus statement J. Vasc. Surg. 2004, 39, 267-269
8. Shi, G.-P.; Munger, J. S.; Meara, J. P.; Rich, D. H.; Chapman, H. A. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease J. Biol. Chem. 1992, 267, 7258-7262
9. Beers, C.; Burich, A.; Kleijmeer, M. J.; Griffith, J. M.; Wong, P.; Rudensky, A. Y. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo J. Immunol. 2005, 174, 1205-1212
10. Qin, Y.; Cao, X.; Guo, J.; Zhang, Y.; Pan, L.; Zhang, H.; Li, H.; Tang, C.; Du, J.; Shi, G.-P. Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice Cardiovasc. Res. 2012, 96, 401-410
11. Saegusa, K.; Ishimaru, N.; Yanagi, K.; Arakaki, R.; Ogawa, K.; Saito, I.; Katunuma, N.; Hayashi, Y. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity J. Clin. Invest. 2002, 110, 361-369
12. Wiener, J. J.; Sun, S.; Thurmond, R. L. Recent advances in the design of cathepsin S inhibitors Curr. Top. Med. Chem. 2010, 10, 717-732
13. Lee-Dutra, A.; Wiener, D. K.; Sun, S. Cathepsin S inhibitors: 2004-2010 Expert Opin. Ther. Pat. 2011, 21, 311-337
14. Palmer, J. T.; Rasnick, D.; Klaus, J. L.; Brömme, D. Vinyl sulfones as mechanism-based cysteine protease inhibitors J. Med. Chem. 1995, 38, 3193-3196
15. Ayesa, S.; Lindquist, C.; Agback, T.; Benkestock, K.; Classon, B.; Henderson, I.; Hewitt, E.; Jansson, K.; Kallin, A.; Sheppard, D.; Samuelsson, B. Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: Effect of sulfonamides P3 substituents on potency and selectivity Bioorg. Med. Chem. 2009, 17, 1307-1324
16. Irie, O.; Kosaka, T.; Ehara, T.; Yokokawa, F.; Kanazawa, T.; Hirao, H.; Iwasaki, A.; Sakaki, J.; Teno, N.; Hitomi, Y.; Iwasaki, G.; Fukaya, H.; Nonomura, K.; Tanabe, K.; Koizumi, S.; Uchiyama, N.; Bevan, S. J.; Malcangio, M.; Gentry, C.; Fox, A. J.; Yaqoob, M.; Culshaw, A. J.; Hallett, A. Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain J. Med. Chem. 2008, 51, 5502-5505
17. Ameriks, M. K.; Bembenek, S. D.; Burdett, M. T.; Choong, I. C.; Edwards, J. P.; Gebauer, D.; Gu, Y.; Karlsson, L.; Purkey, H. E.; Staker, B. L.; Sun, S.; Thurmond, R. L.; Zhu, J. Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 4060-4064 and references cited therein
18. Brömme, D.; Okamoto, K.; Wang, B. B.; Biroc, S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme J. Biol. Chem. 1996, 271, 2126-2132
19. Brömme, D.; Li, Z.; Barnes, M.; Mehler, E. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization Biochemistry 1999, 38, 2377-2385
20. Mason, C. S.; Lamers, M. B. A. C.; Henderson, I. M. J.; Monk, T.; Williams, D. H. Baculoviral expression and characterization of rodent cathepsin S Protein Expression Purif. 2001, 23, 45-54
21. Longo, G. M.; Xiong, W.; Greiner, T. C.; Zhao, Y.; Fiotti, N.; Baxter, T. B. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms J. Clin. Invest. 2002, 110, 625-632
22. Payne, C. D.; Deeg, M. A.; Chan, M.; Tan, L. H.; LaBell, E. S.; Shen, T.; DeBrota, D. J. A single-dose, dose escalation study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of cathepsin S inhibitor, LY3000328, in healthy subjects. Br. J. Clin. Pharmacol. 2014, submitted
23. A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants. http://clinicaltrials.gov/show/NCT01515358.
24. Deng, G.; Gavardinas, K.; Kim, E.; Jadhav, P. K.; Schiffler, M. A. Cathepsin S Inhibitor Compounds. U.S. Patent 8,227,486, July 24, 2012.